Prognostic factors and local recurrence in patients with ductal carcinoma in situ of the breast

Breast Journal

Volumn 4, Issue 5, 1998, Pages 349-362

  Silverstein, Melvin J ^a,b  

^a The Breast Center Inc   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

DCIS; Ductal carcinoma in situ; Noninvasive breast cancer; Prognostic factors

Indexed keywords

ONCOPROTEIN; TUMOR MARKER;

AGING; ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER RECURRENCE; CANCER SIZE; CARCINOMA IN SITU; HUMAN; HUMAN TISSUE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL DECISION MAKING; ONCOGENE NEU; PROGNOSIS;

EID: 0031759938     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1998.450349.x     Document Type: Article

References (35)

1. Patchefsky AS, Schwartz GF, Finkelstein SD, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989;63:731-41.
2. Lennington WJ, Jensen RA, Dalton LW, Page DL. Ductal carcinoma in situ of the breast. Heterogeneity of individual lesions. Cancer 1994;73:118-24.
3. Silverstein MJ, Barth A, Poller DN, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 1995; 31:1425-27.
4. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct Carcinoma in situ: Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer 1982;50:1309-14.
5. Lagios MD. Duct carcinoma in situ: pathology and treatment. Surg Clin N Am 1990;70:853-71.
6. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast duct carcinoma in situ. Lancet 1995; 345:1154-57.
7. Silverstein MJ, Barth A, Waisman JR, et al. Predicting local recurrence in patients with intraductal breast carcinoma (DCIS). Proc Am Soc Clin Oncol 1995;14:117.
8. Bellamy COC, McDonald C, Salter DM, Chetty U, Anderson TJ. Noninvasive ductal carcinoma of the breast. The relevance of histologic categorization. Hum Pathol 1993;24: 16-23.
9. Fisher ER, Constantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Cancer 1995;75:1310-19.
10. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989;63:618-24.
11. Lagios MD. Ductal carcinoma in situ: Controversies in diagnosis, biology, and treatment. Breast J 1995;1:68-78.
12. Ottesen GL, Graversen HP, Bilcher-Toft M, Zedeler K, Andersen JA. Ductal carcinoma in situ of the female breast: short term results of a prospective nationwide study. Am J Surg Pathol 1992;16:1183-96.
13. Poller DN, Silverstein MJ, Galea M, et al. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 1994;7:257-62.
14. Schwartz GF. The role of excision and surveillance alone in subclinical DCIS of the breast. Oncol 1994;8:21-26.
15. Zafrani B, Leroyer A, Fourquet A, et al. Mammographically-detected ductal carcinoma in situ of the breast analysed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins and proliferative activity. Semin Diagn Pathol 1994;11:208-13.
16. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996;77:2267-74.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
19. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34:187-220.
20. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored data. Biometrika 1965;52:203-23.
21. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J R Stat Soc 1972;135:185-207.
22. Fisher ER, Sass R, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 6) 1. Intraductal carcinoma (DCIS). Cancer 1986;57:197-208.
23. Page DL, Rogers LW. Carcinoma in situ (CIS). In: Page DL, Anderson TJ, eds. Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone, 1987;157-92.
24. Tavassoli FA. Intraductal carcinoma. In: Tavassoli FA, ed. Pathology of the Breast. Norwalk, CT: Appleton and Lange, 1992;229-61.
25. Moriya T, Silverberg SG. Intraductal carcinoma (ductal carcinoma in situ) of the breast: a comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma. Cancer 1994;74:2972-78.
26. Patchefsky AS, Schwartz GF, Finkelstein SD, et al. Heterogeneity of intraductal carcinoma of the breast. Cancer 1989;63:731-41.
27. Sloane JP, Ellman R, Anderson TJ, et al. Consistency of histopathological reporting of breast lesions detected by screening: findings of the UK National External Quality Assessment (EQA) Scheme. Eur J Cancer 1994;30A:1414-19.
28. Silverstein MJ, Gierson ED, Colburn WJ, et al. Can intraductal breast carcinoma be excised completely by local excision? Clinical and pathologic predictors. Cancer 1994;73: 2985-89.
29. Silverstein MJ. Predicting residual disease and local recurrence in patients with ductal carcinoma in situ. J Natl Cancer Inst 1997;89:1330-31.
30. Muir R, Aitkenhead AC. The healing of intraductal carcinoma of the mamma. J Pathol Bacterial 1934;38:215-22.
31. Sneige N, McNeese MD, Atkinson EN, et al. Duct carcinoma in situ treated with lumpectomy and irradiation: histopathological analysis of 49 specimens with emphasis on risk factors and long-term results. Hum Pathol 1995;26:642-49.
32. Fourquet A, Zafrani B, Campana F, Clough KB. Institute Curie experience. In: Silverstein MJ, ed. Ductal Carcinoma In Situ of the Breast. Baltimore: Williams and Wilkins, 1997: 391-398.
33. Faverly DRG, Burgers L, Bult P, Holland R. Three dimensional imaging of mammary ductal carcinoma in situ; clinical implications. Semin Diagn Pathol 1994;11:193-98.
34. Schwartz GF, Finkel GC, Garcia JC, Patchefsky AS. Subclinical ductal carcinoma in situ of the breast. Treatment by local excision and surveillance alone. Cancer 1992;70:2468-74.
35. Silverstein MJ, Gierson ED, Waisman JR, Colburn WJ, Gamagami P. Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability. J Am Coll Surg 1995;180:700-4.